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Abstract: While the pathogenesis of chronic obstructive pulmonary disease (COPD) is 
incompletely understood, chronic inﬂ  ammation is a major factor. In fact, the inﬂ  ammatory 
response is abnormal, with CD8+ T-cells, CD68+ macrophages, and neutrophils predominat-
ing in the conducting airways, lung parenchyma, and pulmonary vasculature. Elevated levels 
of the second messenger cAMP can inhibit some inﬂ  ammatory processes. Theophylline has 
long been used in treating asthma; it causes bronchodilation by inhibiting cyclic nucleotide 
phosphodiesterase (PDE), which inactivates cAMP. By inhibiting PDE, theophylline increases 
cAMP, inhibiting inﬂ  ammation and relaxing airway smooth muscle. Rather than one PDE, 
there are now known to be more than 50, with differing activities, substrate preferences, and 
tissue distributions. Thus, the possibility exists of selectively inhibiting only the enzyme(s) in 
the tissue(s) of interest. PDE 4 is the primary cAMP-hydrolyzing enzyme in inﬂ  ammatory and 
immune cells (macrophages, eosinophils, neutrophils). Inhibiting PDE 4 in these cells leads to 
increased cAMP levels, down-regulating the inﬂ  ammatory response. Because PDE 4 is also 
expressed in airway smooth muscle and, in vitro, PDE 4 inhibitors relax lung smooth muscle, 
selective PDE 4 inhibitors are being developed for treating COPD. Clinical studies have been 
conducted with PDE 4 inhibitors; this review concerns those reported to date.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a serious and increasing global 
public health problem; physiologically, it is characterized by progressive, irreversible 
airﬂ  ow obstruction and pathologically, by an abnormal airway inﬂ  ammatory response 
to noxious particles or gases (MacNee 2005a). The COPD patient suffers a reduction 
in forced expiratory volume in 1 second (FEV1), a reduction in the ratio of FEV1 to 
forced vital capacity (FVC), compared with reference values, absolute reductions in 
expiratory airﬂ  ow, and little improvement after treatment with an inhaled broncho-
dilator. Airﬂ  ow limitation in COPD patients results from mucosal inﬂ  ammation and 
edema, bronchoconstriction, increased secretions in the airways, and loss of elastic 
recoil. Patients with COPD can experience ‘exacerbations,’ involving rapid and 
prolonged worsening of symptoms (Seneff et al 1995; Connors et al 1996; Dewan 
et al 2000; Rodriguez-Roisin 2006; Mohan et al 2006). Many are idiopathic, though 
they often involve bacteria; airway inﬂ  ammation in exacerbations can be caused or 
triggered by bacterial antigens (Murphy et al 2000; Blanchard 2002; Murphy 2006; 
Veeramachaneni and Sethi 2006). Increased IL-6, IL-1β, TNF-α, GRO-α, MCP-1, 
and IL-8 levels are found in COPD patient sputum; their levels increase further during 
exacerbations. COPD has many causes and signiﬁ  cant differences in prognosis exist, 
depending on the cause (Barnes 1998; Madison and Irwin 1998).
COPD is already the fourth leading cause of death worldwide, according to the 
World Health Organization (WHO); the WHO estimates that by the year 2020, 
COPD will be the third-leading cause of death and the ﬁ  fth-leading cause of disability 
worldwide (Murray and Lopez 1997). COPD is the fastest-growing cause of death International Journal of COPD 2007:2(4) 518
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in developed nations and is responsible for over 2.7 million 
deaths per year worldwide. In the US, there are currently 
estimated to be 16 million people with COPD. There are 
estimated to be up to 20 million sufferers in Japan, which 
has the world’s highest per capita cigarette consumption and 
a further 8–12 million in Europe. In 2000, COPD accounted 
for over 20 million outpatient visits, 3.4 million emergency 
room visits, 6 million hospitalizations, and 116,500 deaths 
in the US (National Center for Health Statistics 2002). 
Factors associated with COPD, including immobility, 
often lead to secondary health consequences (Polkey and 
Moxham 2006).
Risk factors for the development of COPD include 
cigarette smoking, and occupational exposure to dust and 
chemicals (Senior and Anthonisen 1998; Anthonisen et al 
2002; Fabbri and Hurd 2003; Zaher et al 2004). Smoking 
is the most common cause of COPD and the underlying 
inﬂ  ammation typically persists in ex-smokers. Oxidative 
stress from cigarette smoke is also an issue in COPD (Domej 
et al 2006). Despite this, relatively few smokers ever develop 
COPD (Siafakas and Tzortzaki 2002).
While many details of the pathogenesis of COPD remain 
unclear, chronic inﬂ  ammation is now recognized as a major 
factor, predominantly in small airways and lung parenchyma, 
characterized by increased numbers of macrophages, neutro-
phils, and T-cells (Barnes 2000; Stockley 2002). As recently 
as 1995, the American Thoracic Society issued a statement 
deﬁ  ning COPD without mentioning the underlying inﬂ  am-
mation (American Thoracic Society 1995). Since then, the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines have made it clear that chronic inﬂ  am-
mation throughout the airways, parenchyma, and pulmonary 
vasculature plays a central role (Pauwels et al 2001; GOLD 
2003). The comparatively recent realization of the role of 
airway inﬂ  ammation in COPD has altered thinking with 
regard to potential therapies (Rogers and Giembycz 1998; 
Vignola 2004).
Most pharmacological therapies available for COPD, 
including bronchodilator and anti-inﬂ  ammatory agents, 
were ﬁ  rst developed for treating asthma. The mainstays of 
COPD treatment are inhaled corticosteroids (McEvoy and 
Niewoehner 1998; Borron and deBoisblanc 1998; Pauwels 
2002; Gartlehner et al 2006; D’Souza 2006), supplemen-
tal oxygen (Petty 1998; Austin and Wood-Baker 2006), 
inhaled bronchodilators (Costello 1998; Doherty and 
Briggs 2004), and antibiotics (Taylor 1998), especially in 
severely affected patients (Anthonisen et al 1987; Saint et al 
1995; Adams et al 2001; Miravitlles et al 2002; Donnelly 
and Rogers 2003; Sin et al 2003; Rabe 2006), though the 
use of antibiotics remains controversial (Ram et al 2006). 
Long-acting β2-agonists (LABAs) improve the mucociliary 
component of COPD. Combination therapy with LABAs 
and anticholinergic bronchodilators resulted in modest 
beneﬁ  ts and improved health-related quality of life (Buhl 
and Farmer 2005; Appleton et al 2006). Treatment with 
mucolytics reduced exacerbations and the number of days 
of disability (Poole and Black 2006). The combined use of 
inhaled corticosteroids and LABAs has been demonstrated 
to produce sustained improvements in FEV1 and positive 
effects on quality of life, number of hospitalizations, distance 
walked, and exacerbations (Mahler et al 2002; Szafranski et al 
2003; Sin et al 2004; Miller-Larsson and Selroos 2006; van 
Schayck and Reid 2006). However, all of these treatments are 
essentially palliative and do not impact COPD progression 
(Hay 2000; Gamble et al 2003; Antoniu 2006a).
A further complication in drug development and 
therapy is that it can be difﬁ  cult to determine the efﬁ  cacy 
of therapy, because COPD has a long preclinical stage, 
is progressive, and patients generally do not present for 
treatment until their lung function is already seriously 
impaired. Moreover, because COPD involves irreversible 
loss of elasticity, destruction of the alveolar wall, and 
peribronchial ﬁ  brosis, there is often little room for clinical 
improvement.
Smoking cessation remains the most effective interven-
tion for COPD. Indeed, to date, it is the only intervention 
shown to stop the decline in lung function, but it does not 
resolve the underlying inﬂ  ammation, which persists even in 
ex-smokers. Smoking cessation is typically best achieved 
by a multifactor approach, including the use of bupropion, 
a nicotine replacement product, and behavior modiﬁ  cation 
(Richmond and Zwar 2003).
In COPD, there is an abnormal inﬂ  ammatory response, 
characterized by a predominance of CD8+ T-cells, CD68+  
macrophages, and neutrophils in the conducting airways, 
lung parenchyma, and pulmonary vasculature (Soto and 
Hanania 2005; O’Donnell et al 2006; Wright and Churg 
2006). Inﬂ  ammatory mediators involved in COPD include 
lipids, inﬂ  ammatory peptides, reactive oxygen and nitrogen 
species, chemokines, cytokines, and growth factors. COPD 
pathology also includes airway remodeling and muco-
ciliary dysfunction (mucus hypersecretion and decreased 
mucus transport). Corticosteroids reduce the number of 
mast cells, but CD8+ and CD68+ cells, and neutrophils, 
are little affected (Jeffery 2005). Inﬂ  ammation in COPD 
is not suppressed by corticosteroids, consistent with it International Journal of COPD 2007:2(4) 519
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being neutrophil-, not eosinophil-mediated. Corticosteroids 
also do not inhibit the increased concentrations of IL-8 
and TNF-α (both neutrophil chemoattractants) found in 
induced sputum from COPD patients. Neutrophil-derived 
proteases, including neutrophil elastase and matrix metal-
loproteinases (MMPs), are involved in the inﬂ  ammatory 
process and are responsible for the destruction of elastin 
ﬁ  bers in the lung parenchyma (Mercer et al 2005; Gueders 
et al 2006). MMPs play important roles in the proteolytic 
degradation of extracellular matrix (ECM), in physiological 
and pathological processes (Corbel, Belleguic et al 2002). 
PDE 4 inhibitors can reduce MMP activity and the produc-
tion of MMPs in human lung ﬁ  broblasts stimulated with 
pro-inﬂ  ammatory cytokines (Lagente et al 2005). In COPD, 
abnormal remodeling results in increased deposition of ECM 
and collagen in lungs, because of an imbalance of MMPs 
and TIMPs (Jeffery 2001). Fibroblast/myoﬁ  broblast pro-
liferation and activation also occur, increasing production 
of ECM-degrading enzymes (Crouch 1990; Segura-Valdez 
et al 2000). Additionally, over-expression of cytokines and 
growth factors stimulates lung ﬁ  broblasts to synthesize 
increased amounts of collagen and MMPs, including MMP-1 
(collagenase-1) and MMP-2 and MMP-9 (gelatinases 
A and B) (Sasaki et al 2000; Zhu et al 2001).
It is now generally accepted that bronchial asthma is also 
a chronic inﬂ  ammatory disease (Barnes et al 1988; Barnes 
1995). The central role of inﬂ  ammation of the airways in 
asthma’s pathogenesis is consistent with the efﬁ  cacy of 
corticosteroids in controlling clinical symptoms. Eosinophils 
are important in initiating and continuing the inﬂ  ammatory 
state (Holgate et al 1987; Bruijnzeel 1989; Underwood et al 
1994; Teixeira et al 1997), while other inﬂ  ammatory cells, 
including lymphocytes, also inﬁ  ltrate the airways (Holgate 
et al 1987; Teixeira et al 1997). The familiar acute symptoms 
of asthma are the result of airway smooth muscle contraction. 
While recognition of the key role of inﬂ  ammation has led 
to an emphasis on anti-inﬂ  ammatory therapy in asthma, a 
signiﬁ  cant minority of patients remains poorly controlled and 
some exhibit accelerated declines in lung function, consistent 
with airway remodeling (Martin and Reid 2006). Reversal or 
prevention of structural changes in remodeling may require 
additional therapy (Burgess et al 2006).
There is currently no cure for asthma; treatment depends 
primarily on inhaled glucocorticoids to reduce inﬂ  ammation 
(Taylor 1998; Petty 1998), and inhaled bronchodilators to 
reduce symptoms (Torphy 1994; Costello 1998; Georgitis 
1999; DeKorte 2003). Such treatments, however, do not 
address disease progression.
COPD and asthma are both characterized by airﬂ  ow obstruc-
tion, but they are distinct in terms of risk factors and clinical pre-
sentation. While both involve chronic inﬂ  ammation and cellular 
inﬁ  ltration and activation, different cell types are implicated 
and there are differences in the inﬂ  ammatory states (Giembycz 
2000; Fabbri and Hurd 2003; Barnes 2006). In COPD, neutro-
phil inﬁ  ltration into the airways and their activation appear to 
be key (Stockley 2002); in asthma, the inﬂ  ammatory response 
involves airway inﬁ  ltration by activated eosinophils and lym-
phocytes, and T-cell activation of the allergic response (Holgate 
et al 1987; Saetta et al 1998; Barnes 2006). While macrophages 
are present in both conditions, the major controller cells are 
CD8+ T-cells in COPD (O’Shaughnessy et al 1997; Saetta et al 
1998) and CD4+ T-cells in asthma. IL-1, IL-8, and TNF-α are 
the key cytokines in COPD, while in asthma, IL-4, IL-5, and 
IL-13 are more important. There are differences in histopatho-
logical features of lung biopsies between COPD patients and 
asthmatics; COPD patients have many fewer eosinophils in 
lung tissue than asthmatics.
While the early phases of COPD and asthma are dis-
tinguishable, there are common features, including airway 
hyper-responsiveness and mucus hypersecretion. MUC5AC 
is a major mucin gene expressed in the airways; its expres-
sion is increased in COPD and asthmatic patients. At least 
in vitro, epidermal growth factor stimulates MUC5AC 
mRNA and protein expression; this can be reversed by PDE 
4 inhibitors, which may contribute to their clinical efﬁ  cacy 
in COPD and asthma (Mata et al 2005). Similar structural 
and ﬁ  brotic changes make COPD and asthma much less 
distinguishable in extreme cases; the chronic phases of both 
involve inﬂ  ammatory responses, alveolar detachment, mucus 
hypersecretion, and subepithelial ﬁ  brosis. The two conditions 
have been linked epidemiologically; adults with asthma are 
up to 12 times more likely to develop COPD over time than 
those without (Guerra 2005).
Theophylline
Theophylline and related xanthine compounds have been 
used for decades to treat asthma (Weinberger 1988; Torphy 
and Undem 1991; Manganiello et al 1995; Dent and 
Giembycz 1996; Weinberger and Hendeles 1996; Torphy 
1998; Ram et al 2002; Barnes 2003; Barr et al 2003). The 
use of these drugs has been limited, however, by their side 
effects and modest efﬁ  cacy (Persson 1986; Rabe et al 1995). 
Additionally, theophylline is a difﬁ  cult drug to use, requir-
ing titration and plasma monitoring, because of the risk of 
cardiovascular and CNS side effects, even at therapeutic 
doses (Boswell-Smith, Cazzola et al 2006).International Journal of COPD 2007:2(4) 520
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The second messenger cyclic 3′,5′-adenosine monophos-
phate (cAMP) controls many cellular functions and it is well 
established that an elevated cAMP level can inhibit some 
inﬂ  ammatory processes. Thus, inhibitors of enzymes that 
catalyze cAMP hydrolysis would seem to be good candidates 
to treat inﬂ  ammatory conditions.
Phosphodiesterase (PDE)
Theophylline is believed to cause bronchodilation by 
inhibiting cyclic nucleotide phosphodiesterase (PDE), 
an enzyme that catalyzes the hydrolysis of cAMP and 
cyclic 3′,5′-guanosine monophosphate (cGMP) to inactive 
5'-nucleotide products (Muller et al 1996), cAMP and cGMP 
exhibit many intracellular effects, mediated largely through 
their stimulatory effect on multisubstrate protein kinases 
(Torphy and Undem 1991; Montminy 1997; Daniel et al 
1998; Spina 2003). By inhibiting PDE, theophylline increases 
the level of cAMP and cGMP, resulting in relaxation of 
airway smooth muscle and inhibition of inﬂ  ammatory cell 
activation (Holgate et al 1987; Bryson and Rodger 1987; 
Schramm and Grunstein 1992; Cortijo et al 1993; Kotlikoff 
and Kamm 1996; Spina 2003).
Theophylline is now known to have many properties in 
addition to that of a bronchodilator (Persson 1986; Sullivan 
et al 1994; Rabe et al 1995; D’Alonzo 1996; Weinberger 
and Hendeles 1996; Vassallo and Lipsky 1998). Theophyl-
line also causes pulmonary arterial vasodilatation, enhances 
diaphragmatic contractility, and increases CNS respiratory 
drive. Theophylline is a cardiac ionotrope and chromotrope. 
It is also a weak diuretic and increases mucociliary sweep. 
Theophylline has anti-inﬂ  ammatory effects in COPD, reduc-
ing neutrophil counts, IL-8, and the total number inﬂ  amma-
tory cells in sputum. Theophylline is also subject to many 
drug interactions and has adenosine receptor antagonist 
activity (Barnes 2003).
Far from there being a single PDE, it is now clear that 
there are many with differing activities, substrate preferences, 
and tissue distributions (Nicholson et al 1991; Thompson 
1991; Lowe and Cheng 1992; Beavo et al 1994; Manganiello 
et al 1995; Torphy 1998; Silver et al 1988; Matsumoto et al 
2003); theophylline is actually a non-speciﬁ  c PDE inhibitor 
(Persson 1986; Rabe et al 1995; D’Alonzo 1996; Weinberger 
and Hendeles 1996; Vassallo and Lipsky 1998). Some of its 
various properties and side-effects have been attributed to 
non-selective inhibition of PDEs (Barnes 2003).
Indeed, there are believed to be at least 11 gene families of 
PDE enzymes in mammals, encoding more than 50 enzymes, 
because of alternative splicing and alternative transcriptional 
start sites (Bolger 1994; Lobban et al 1994; Horton et al 1995; 
Bushnik and Conti 1996; Jin et al 1998; Houslay et al 1998; 
Conti and Jin 1999; Giembycz 2000; Giembycz 2001; Scapin 
et al 2004; Giembycz 2005a; Bender and Beavo 2006). PDE 
enzymes share approximately 25% sequence identity over 
the conserved catalytic domain of about 300 amino acids 
(Ke 2004). While all PDEs catalyze the hydrolysis of cAMP 
and/or cGMP, the enzymes differ in their biochemical and 
pharmacological properties and exhibit different afﬁ  nities 
for various inhibitors (Silver et al 1988; Torphy and Undem 
1991; Manganiello et al 1995; Muller et al 1996; Torphy 
1998). PDE 4, PDE 7, and PDE 8 are speciﬁ  c for cAMP 
(Conti and Yin 1999; Soderling and Beavo 2000). This diver-
sity of enzyme type and tissue-speciﬁ  c expression raises the 
possibility of selectively inhibiting only the enzyme(s) in the 
tissue(s) of interest, if sufﬁ  ciently speciﬁ  c inhibitors can be 
found (Giembycz and Dent 1992; Card et al 2004).
PDE 4 in COPD
With regard to COPD, PDE 4 is the primary cAMP-
hydrolyzing enzyme in inﬂ  ammatory and immune cells, 
especially macrophages, eosinophils, and neutrophils, all of 
which are found in the lungs of COPD and asthma patients 
(Torphy et al 1992; Karlsson and Aldous 1997; De Brito 
et al 1997; Wang et al 1999; Torphy and Page 2000). Inhibi-
tion of PDE 4 leads to elevated cAMP levels in these cells, 
down-regulating the inflammatory response (Dyke and 
Montana 2002).
PDE 4 has also attracted much attention because it is 
expressed in airway smooth muscle (Ashton et al 1994; 
Undem et al 1994; Nicholson et al 1995; Kerstjens and 
Timens 2003; Mehats et al 2003; Lipworth 2005; Fan Chung 
2006). In vitro, PDE 4 inhibitors relax lung smooth muscle 
(Undem et al 1994; Dent and Giembycz 1995). In COPD and 
asthma, a selective PDE 4 inhibitor with combined bronchodi-
latory and anti-inﬂ  ammatory properties would seem desirable 
(Nicholson and Shahid 1994; Lombardo 1995; Palfreyman 
1995; Cavalia and Frith 1995; Palfreyman and Souness 1996; 
Karlsson and Aldous 1997; Compton et al 2001; Giembycz 
2002; Jacob et al 2002; Soto and Hanania 2005).
PDE 4 inhibitors in COPD
So, because PDE 4 inhibitors suppress inﬂ  ammatory func-
tions in several cell types involved in COPD and asthma 
(Huang and Mancini 2006) and because, at least in vitro, 
PDE 4 inhibitors relax lung smooth muscle, selective PDE 4 
inhibitors, originally intended for use in treating depression 
(Renau 2004), have been developed for the treatment of International Journal of COPD 2007:2(4) 521
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COPD and asthma (Torphy et al 1999; Spina 2000; Huang 
et al 2001; Spina 2004; Giembycz 2005a, 2005b; Lagente et al 
2005; Boswell-Smith, Spina et al 2006). PDE 4 enzymes are 
strongly inhibited by the antidepressant drug rolipram (Pinto 
et al 1993), which decreases the inﬂ  ux of inﬂ  ammatory cells at 
sites of inﬂ  ammation (Lagente et al 1994; Lagente et al 1995; 
Alves et al 1996). PDE 4 inhibitors down-regulate cytokine 
production in inﬂ  ammatory cells, in vivo and in vitro (Undem 
et al 1994; Dent and Giembycz 1995). TNF-α is an important 
inﬂ  ammatory cytokine in COPD; its release is reduced by 
PDE 4 inhibitors (Souness et al 1996; Chambers et al 1997; 
Griswold et al 1998; Gonçalves de Moraes et al 1998; Corbel, 
Belleguic et al 2002). Some PDE 4 inhibitors, including cilo-
milast and AWD 12-281, can inhibit neutrophil degranulation, 
a property not shared by theophylline (Ezeamuzie 2001; Jones 
et al 2005). PDE 4 inhibitors reduce overproduction of other 
pro-inﬂ  ammatory mediators, including arachidonic acid and 
leukotrienes (Torphy 1998). PDE 4 inhibitors also inhibit 
cellular trafﬁ  cking and microvascular leakage, production of 
reactive oxygen species, and cell adhesion molecule expres-
sion in vitro and in vivo (Sanz et al 2005). PDE 4 inhibitors, 
including cilomilast and CI-1044, inhibit LPS-stimulated 
TNF-α production in whole blood from COPD patients 
(Burnouf et al 2000; Ouagued et al 2005).
There are now thought to be at least four PDE 4s, A, B, C, 
and D, derived from four genes (Lobbam et al 1994; Muller 
et al 1996; Torphy 1998; Conti and Jin 1999; Matsumoto 
et al 2003). Alternative splicing and alternative promoters 
add further complexity (Manganiello et al 1995; Horton et al 
1995; Torphy 1998). Indeed, the four genes encode more than 
16 PDE 4 isoforms, which can be divided into short (∼65–75 
kDa) and long forms (∼80–130 kDa); the difference between 
the short and long forms lies in the N-terminal region (Bolger 
et al 1997; Huston et al 2006). PDE 4 isoforms are regulated 
by extracellular signal-related protein kinase (ERK), which 
can phosphorylate PDE 4 (Houslay and Adams 2003).
The four PDE 4 genes are differentially expressed 
in various tissues (Silver et al 1988; Lobbam et al 1994; 
Manganiello et al 1995; Horton et al 1995; Muller et al 1996; 
Torphy 1998). PDE 4A is expressed in many tissues, but not 
in neutrophils (Wang et al 1999). PDE 4B is also widely 
expressed and is the predominant PDE 4 subtype in mono-
cytes and neutrophils (Wang et al 1999), but is not found in 
cortex or epithelial cells (Jin et al 1998). Upregulation of 
the PDE 4B enzyme in response to pro-inﬂ  ammatory agents 
suggest that it has a role in inﬂ  ammatory processes (Manning 
et al 1999). PDE 4C is expressed in lung and testis, but not 
in circulating inﬂ  ammatory cells, cortex, or hippocampus 
(Obernolte et al 1997; Manning et al 1999; Martin-Chouly 
et al 2004). PDE 4D is highly expressed in lung, cortex, 
cerebellum, and T-cells (Erdogan and Houslay 1997; Jin 
et al 1998). PDE 4D also plays an important role in airway 
smooth muscle contraction (Mehats et al 2003).
A major issue with early PDE 4 inhibitors was their side 
effect proﬁ  le; the signature side effects are largely gastroin-
testinal (nausea, vomiting, increased gastric acid secretion) 
and limited the therapeutic use of PDE 4 inhibitors (Dyke 
and Montana 2002). The second generation of more selective 
inhibitors, such as cilomilast and roﬂ  umilast, have improved 
side effect proﬁ  les and have shown clinical efﬁ  cacy in COPD 
and asthma (Barnette 1999; Spina 2000; Lagente et al 2005). 
However, even cilomilast and roﬂ  umilast, the most advanced 
clinical candidates, discussed below, cause some degree of 
emesis (Spina 2003).
It is now thought that the desirable anti-inﬂ  ammatory 
properties and unwanted side effects of nausea and emesis are 
associated with distinct biochemical activities (Torphy et al 
1992; Jacobitz et al 1996; Barnette et al 1996; Souness et al 
1997; Souness and Rao 1997). Speciﬁ  cally, the side effects 
are believed to be associated with the so-called ‘high-afﬁ  nity 
rolipram binding site’ (HARBS) (Barnette et al 1995; Muller 
et al 1996; Jacobitz et al 1996; Kelly et al 1996; Torphy 1998) 
and/or inhibition of the form of PDE 4 found in the CNS 
(Barnette et al 1996). The exact nature of HARBS remains 
unclear, although it has been described as a conformer of 
PDE 4 (Souness and Rao 1997; Barnette et al 1998). Using 
mice deﬁ  cient in PDE 4B or PDE 4D, it appears that emesis 
is the result of selective inhibition of PDE 4D (Robichaud 
et al 2002; Lipworth 2005), which is unfortunate, because 
the most clinically advanced PDE 4 inhibitors are selective 
for PDE 4D. Also, from animal studies, it appears that the 
nausea and vomiting are produced via the CNS, though there 
may also be direct effects on the gastrointestinal system 
(Barnette 1999).
While beyond the scope of this review, it has been 
proposed that PDE 4 inhibitors may be useful in treating 
inﬂ  ammatory bowel disease (Banner and Trevethick 2004), 
cystic ﬁ  brosis (Liu et al 2005), pulmonary arterial hyperten-
sion (Growcott et al 2006), myeloid and lymphoid malig-
nancies (Lerner and Epstein 2006), Alzheimer’s disease 
(Ghavami et al 2006), rheumatoid arthritis and multiple 
sclerosis (Dyke and Montana 2002), infection-induced 
preterm labor (Oger et al 2004), depression (Wong et al 
2006), and allergic disease (Crocker and Townley 1999). 
Varying degrees of in vitro, in vivo, and clinical data exist 
to support these claims.International Journal of COPD 2007:2(4) 522
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So, after that theoretical buildup, we reach the proof 
of the pudding; clinical studies have been conducted with 
PDE 4 inhibitors. A potent, but not-very-selective, PDE 4 
inhibitor is approved in Japan and is used clinically, includ-
ing for treating asthma. Another is awaiting approval in the 
US. One is in advanced clinical development and others are 
at earlier stages.
Ibudilast
The drug ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]
pyridine) is a nonselective PDE inhibitor. It is approved in 
Japan and has been widely used to treat bronchial asthma 
and ischemic stroke. Ibudilast preferentially inhibits PDE 
3A, PDE 4, PDE 10, and PDE 11. Ibudilast potently inhibits 
puriﬁ  ed human PDE 4A, 4B, 4C and 4D with IC50 values of 
54, 65, 239 and 166 nM, respectively (Huang et al 2006). 
It may be useful in treating a range of neurological condi-
tions, linked to its ability to elevate cellular cyclic nucleotide 
concentrations (Gibson et al 2006).
Cilomilast
Cilomilast is a second-generation PDE 4 inhibitor that was 
developed to separate activity at the HARBS and PDE 4 
(Christensen et al 1998; Barnette et al 1998; Griswold et al 
1998; Underwood et al 1998; Torphy et al 1999). Cilomilast 
is as strong an anti-inﬂ  ammatory as rolipram, but causes 
much less nausea and gastric acid secretion. Cilomilast is 
also negatively charged at physiological pH, limiting its 
penetration into the CNS.
Cilomilast is being developed as a treatment for COPD; 
the drug has been assessed in phase III trials (Norman 1999; 
Norman 2000; Barnette and Underwood 2000; Torphy 
and Page 2000; Martina et al 2006). The compound had 
previously been in development for asthma, and phase II 
trials were conducted in the US and Japan in 2001; however, 
development for asthma was apparently discontinued.
Cilomilast is a potent (Ki = 92 nM), selective PDE 
4 inhibitor (Christensen et al 1998; Barnette et al 1998; 
Griswold et al 1998; Underwood et al 1998). Cilomilast is 
considerably more selective for PDE 4D (IC50 = 12 nM) 
than 4A (IC50 = 115 nM), 4B (IC50 = 86 nM), or 4C 
(IC50 = 308 nM). The drug is essentially inactive against 
PDEs 1, 2, 3, 5, and 7 (Christensen et al 1998). Cilomi-
last inhibited human TNF-α production and PDE 4, and 
increased intracellular cAMP levels in both neutrophils 
and PBMCs (Chambers et al 1997). Cilomilast (10 μM) 
inhibited the degradation of three-dimensional collagen 
gel by ﬁ  broblasts (Kohyama et al 2002).
The anti-inﬂ  ammatory effects of cilomilast have been 
assessed in bronchial epithelial cells and sputum cells from 
smokers, COPD patients, and normal controls (Proﬁ  ta et al 
2003). TNF-α and IL-8 were released at a signiﬁ  cantly 
higher level in bronchial epithelial and sputum cells from 
patients with COPD than in controls or smokers. Cilomilast 
signiﬁ  cantly reduced TNF-α release by bronchial epithelial 
and sputum cells, and GM-CSF release by sputum cells; 
IL-8 release was not signiﬁ  cantly changed. Thus, cilomilast 
inhibited the production of some neutrophil chemoattractants 
by airway cells (Proﬁ  ta et al 2003). In bronchial biopsies 
from COPD patients, cilomilast treatment was associated 
with reductions in CD8+ and CD68+ cells; both cell types 
are increased in COPD and correlate with disease severity 
(Gamble et al 2003).
The cilomilast COPD clinical program included over 
4000 patients in phase II and III trials. Evidence of safety 
and efﬁ  cacy was based on four pivotal trials, involving 2883 
patients. In addition, two phase-III open-label extension 
studies followed 1069 cilomilast patients for as long as three 
years. Inclusion criteria for the pivotal studies were patients 
between the ages of 40 and 80-years, with a diagnosis of 
COPD. Two primary endpoints were used: FEV1 and total 
score on the St George’s respiratory questionnaire (SGRQ), 
a self-administered questionnaire intended to determine the 
impact of chronic respiratory disease on health-related quality 
of life and well-being.
To date, four clinical trials have evaluated the efﬁ  cacy of 
cilomilast and demonstrated improvement in lung function 
(FEV1) and quality of life and reduction in the occurrence of 
COPD exacerbations, compared with placebo. Cilomilast was 
generally well tolerated, with adverse effects being overall 
mild and self-limiting.
The phase I and phase II studies demonstrated that cilo-
milast signiﬁ  cantly improved lung function and quality of 
life to a clinically meaningful extent. A phase III program 
followed, to evaluate efﬁ  cacy, safety, and mechanism of 
action.
By late 2003, GSK had performed four pivotal studies of 
cilomilast in a total of 2883 patients (n = 647 (study 039), 700 
(study 042), 711 (study 091) and 825 (study 156)), compar-
ing cilomilast (15 mg bid) with placebo over 24-weeks. Data 
from these trials, relating to various combinations of patients, 
have now been reported in several publications.
Phase III results in 2058 stable COPD patients were 
reported comparing cilomilast (15 mg bid for 6-months) with 
placebo. Cilomilast caused a sustained improvement in lung 
function and a reduction in the risk of exacerbation. Using International Journal of COPD 2007:2(4) 523
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the SGRQ to assess quality of life, there was an improvement 
in health status in the cilomilast-treated group.
In a 6-month study, involving 647 patients with stable 
COPD (431 received 15 mg cilomilast bid and 216 received 
placebo), the cilomilast-treated patients exhibited an 
improved health status (assessed by SGRQ). These patients 
also demonstrated improved lung function (FEV1: 40 mL 
improvement over placebo), reduced healthcare resources 
utilization (physician visits, emergency room visits, 
hospitalization), and a lower rate of COPD exacerbation 
(39% lower than placebo).
After a 4-week, single-blind, run-in phase, 1411 patients 
with stable COPD received placebo or cilomilast (15 mg bid) 
for 24-weeks. FEV1 was maintained in patients receiving 
cilomilast versus placebo, with a treatment difference of 
300 mL. Cilomilast achieved a clinically signiﬁ  cant reduction 
(26%) in the risk of moderate-to-severe COPD exacerbations, 
compared with placebo.
Thus, two of the four pivotal studies (studies 039 
and 156) reached clinical significance and two (042 and 
091) did not. There was a mean change in FEV1 of 10 mL 
from baseline following cilomilast treatment in the two 
positive trials, compared with 20 and 30 mL reductions, 
for placebo in these trials (for studies 156 and 039, 
respectively).
Side effects and contraindications
GI-related side effects, including nausea, diarrhea, dyspepsia, 
vomiting, and abdominal pain, have been observed; they are 
believed to be dose-related and were monitored speciﬁ  cally 
because of preclinical studies ﬁ  nding vasculitis in cilomilast-
treated mice and rats. Ischemic colitis (a consequence of 
mesenteric arteritis) was a monitored adverse event in the 
clinical program; it was observed in three patients receiving 
cilomilast and in two receiving placebo, a low rate consistent 
with the normal incidence in the general population. The 
frequency of GI symptoms that concerned the patients or 
interfered with daily activities was 3-fold higher in patients 
receiving cilomilast than placebo.
Roﬂ  umilast
Roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-
N-[3,5-dichloropyrid-4-yl]-benzamide) is a potent and selec-
tive PDE 4 inhibitor. It is being developed as an oral therapy 
for COPD and asthma (Reid 2002; Christie 2005; Cowan 
2005; Antoniu 2006b; Boswell-Smith and Page 2006). It is 
an effective anti-inﬂ  ammatory agent in COPD and asthma. 
Animal data and clinical trials to date have demonstrated 
favorable efﬁ  cacy and safety, and no documented drug 
interactions (Hatzelmann and Schudt 2001).
Roﬂ  umilast inhibits PDE 4 activity in human neutrophils 
(IC50 = 0.8 nM), without affecting PDE 1, 2, 3, or 5, even 
at 10,000-fold higher concentrations. Roﬂ  umilast has good 
bioavailability following oral administration, a long half-life 
(∼10 h), and an active metabolite (roﬂ  umilast-N-oxide, with 
a half-life of ∼20 h). Roﬂ  umilast is approximately equipotent 
with its major in vivo metabolite (roﬂ  umilast-N-oxide).
It can be given once a day; it has been studied as an 
oral tablet at doses of 250 or 500 μg/day. Roﬂ  umilast is 
thus convenient to administer and has a favorable side 
effect proﬁ  le in clinical studies reported to date (Karish and 
Gagnon 2006).
Roﬂ  umilast has a range of anti-inﬂ  ammatory proper-
ties and has potential for treating inﬂ  ammatory diseases. 
Roﬂ  umilast increases levels of cellular cAMP and inhib-
its microvascular leakage, trafficking, and the release 
of cytokines and chemokines from inflammatory cells 
(Christie et al 2005). Roflumilast apparently mediates 
some of its anti-inﬂ  ammatory effects by inducing heme 
oxygenase-1 expression in macrophages (Kwak et al 2005). 
The anti-inﬂ  ammatory and immunomodulatory potential of 
roﬂ  umilast has been assessed in human leukocytes. Regard-
less of cell type and the response investigated, the IC50 values 
were in a narrow range (2–21 nM), similar to that of roﬂ  umi-
last N-oxide (3–40 nM) (Hatzelmann and Schudt 2001).
Roﬂ  umilast has shown encouraging efﬁ  cacy in patients 
with COPD, with signiﬁ  cant improvements observed in 
FEV1 and PEFR versus baseline (Cowan 2005). COPD 
patients receiving roﬂ  umilast experienced fewer exacerba-
tions. The most common adverse effects reported in clini-
cal trials were diarrhea, nausea, headache, and abdominal 
pain (Cowan 2005). In a biopsy study of COPD patients, 
roflumilast significantly reduced the numbers of CD8+ 
T-cells and caused lesser reductions in the numbers of CD4+ 
T-cells and neutrophils, and no changes in the expression of 
IL-8 or TNF-α.
A 6-month dose ranging study of roﬂ  umilast in COPD 
patients has been reported. Patients receiving roﬂ  umilast 
exhibited a signiﬁ  cant, although modest, improvement in 
FEV1. Patients in the roﬂ  umilast group had a 48% reduction 
in the number of exacerbations, as compared with an 8% 
reduction in the placebo group.
In a phase III, multicenter, double-blind, randomized, 
placebo-controlled study undertaken in an outpatient setting, 
1411 patients with moderate-to-severe COPD were randomly 
assigned to receive roﬂ  umilast 250 μg (n = 576), roﬂ  umilast International Journal of COPD 2007:2(4) 524
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500 μg (n = 555), or placebo (n = 280) given orally once daily 
for 24-weeks. Primary outcomes were post-bronchodilator 
FEV1 and health-related quality of life. Secondary outcomes 
included exacerbations. 1157 (82%) patients completed 
the study. Post-bronchodilator FEV1 at the end of treat-
ment signiﬁ  cantly improved with roﬂ  umilast 250 μg and 
500 μg, compared with placebo. Most adverse events were 
mild-to-moderate in intensity and resolved during the study. 
Roﬂ  umilast improved lung function and reduced exacerba-
tions compared with placebo (Rabe et al 2005).
Roﬂ  umilast has also been assessed in several clinical 
studies of asthma. In a double-blind, randomized study, 
roﬂ  umilast was compared with inhaled beclomethasone 
dipropionate. 499 patients (FEV1 = 50%–85% predicted) 
received roﬂ  umilast 500 μg once daily or beclomethasone 
dipropionate 200 μg twice daily for 12 weeks. Roﬂ  umilast 
and beclomethasone dipropionate signiﬁ  cantly improved 
FEV1 and FVC. Once daily roﬂ  umilast (500 μg oral) was 
comparable with inhaled twice-daily beclomethasone 
dipropionate (400 μg/d) in improving pulmonary function 
and asthma symptoms and reducing rescue medication use 
(Bousquet et al 2006). In a dose-ranging study of roﬂ  umilast 
in patients with mild-to-moderate asthma, patients (n = 693) 
were randomized in a double-blind, parallel-group manner. 
After a 1–3-week placebo run-in period, patients (mean FEV1 
73% of predicted) were randomized to receive roﬂ  umilast 
100, 250, or 500 μg once daily for 12-week. The primary 
end point was change in FEV1 from baseline. Secondary 
end points included change in morning and evening peak 
expiratory ﬂ  ow from baseline. Roﬂ  umilast signiﬁ  cantly 
increased FEV1 (improvements from baseline at the last 
visit were 260, 320, and 400 mL for the 100, 250, and 500 
μg doses, respectively). Roﬂ  umilast was well tolerated at 
all doses tested; most adverse events were mild to moderate 
in intensity and transient (Bateman et al 2006). Roﬂ  umilast 
was assessed in a placebo-controlled, randomized, double-
blind, crossover study in 16 patients with exercise-induced 
asthma. Patients received placebo or roﬂ  umilast (500 μg/d) 
for 28 d. Exercise challenge was performed 1 h after dosing 
on days 1, 14, and 28. FEV1 was measured before exercise 
challenge, immediately after the end of exercise, and then 
1, 3, 5, 7, 9, and 12 min later. The mean percentage fall in 
FEV1 after exercise was reduced by 41%, compared with 
placebo. The median TNF-α level decreased by 21% during 
roﬂ  umilast treatment, but remained constant with the placebo. 
Roﬂ  umilast was effective in treating exercise-induced asthma 
and there was a signiﬁ  cant reduction of TNF-α levels ex vivo 
(Timmer et al 2002).
Roﬂ  umilast’s anti-allergy properties have been assessed 
in several clinical studies. The efﬁ  cacy of oral roﬂ  umilast 
(500 μg/day) has been investigated in allergic rhinitis, in a 
randomized, placebo-controlled, double-blind, crossover 
study. Twenty ﬁ  ve people (16 male, 9 female; median age, 
28 years) with histories of allergic rhinitis, but who were 
asymptomatic at screening, received roﬂ  umilast (500 μg 
once daily) and placebo for 9 d each with a washout period 
of at least 14 d between treatments. Controlled intranasal 
allergen provocation with pollen extracts was performed 
daily beginning on the third day of treatment, ∼2 h after drug 
administration. After allergen provocation, rhinal airﬂ  ow was 
measured and subjective symptoms (obstruction, itching, 
rhinorrhea) were assessed. Rhinal airﬂ  ow improved during 
roﬂ  umilast treatment and was signiﬁ  cantly higher at study 
day 9 than with placebo. Thus, roﬂ  umilast, effectively con-
trolled symptoms of allergic rhinitis (Schmidt et al 2001).
The effects of repeated doses of roﬂ  umilast (250 or 
500 μg oral) on asthmatic airway responses to allergen 
were examined in a randomized, double-blind, placebo-
controlled, crossover study. Patients (n = 23) with mild 
asthma (FEV1   70% of predicted value) participated in 3 
treatment periods (7–10 d), separated by washout periods 
(2–5-week). Patients received roﬂ  umilast (250 μg or 500 
μg oral) or placebo once daily. Allergen challenge was per-
formed at the end of each treatment period, followed by FEV1 
measurements over the next 24 h. Once-daily oral roﬂ  umilast 
attenuated late asthmatic reactions and, to a lesser degree, 
early asthmatic reactions to allergen in patients with mild 
allergic asthma (van Schalkwyk et al 2005).
Several studies on roﬂ  umilast’s pharmacokinetic prop-
erties and metabolism have been reported. In an open, 
randomized, single-dose crossover study, the effects of a 
high-fat meal on the pharmacokinetics of roﬂ  umilast and 
its N-oxide metabolite were investigated. Twelve healthy 
subjects received roﬂ  umilast (2 × 250 μg orally) after an 
overnight fast and after breakfast. Blood was sampled up 
to 54 h for pharmacokinetic proﬁ  ling of roﬂ  umilast and 
its N-oxide. After the meal, roﬂ  umilast Cmax was modestly 
reduced and the N-oxide Cmax was unchanged. Roﬂ  umilast 
tmax was delayed in the fed (2 h) versus the fasted state (1 h), 
while the N-oxide tmax was unchanged. No signiﬁ  cant food 
effect was seen on roﬂ  umilast or the N-oxide AUC0–last or 
AUC0–8. Thus, roﬂ  umilast can be taken with or without food 
(Hauns et al 2006).
Roﬂ  umilast is partly metabolized by cytochrome P450 
(CYP) 3A4, and may inhibit its activity. Therapeutic 
steady-state concentrations of roﬂ  umilast and its active International Journal of COPD 2007:2(4) 525
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metabolite roﬂ  umilast N-oxide did not alter the metabolism 
of the CYP3A substrate midazolam in healthy adult male 
subjects, suggesting that roﬂ  umilast is not likely to affect 
the clearance of drugs that are metabolized by CYP3A4 
(Nassr et al 2006).
BAY 19-8004
The effects of a 1-week treatment with BAY 19-8004 (5 mg 
once per day) have been examined on trough FEV1 and 
markers of inﬂ  ammation in induced sputum in patients with 
COPD or asthma. Eleven patients with COPD (FEV1 ∼60% 
predicted, all smokers) and 7 patients with asthma (FEV1 
∼70% predicted, all non-smokers) took part in a randomized, 
double-blind, placebo-controlled trial. FEV1 was measured 
before and after 1 week of treatment; sputum was induced by 
4.5% saline inhalation on the last day of treatment. FEV1 did 
not improve during either treatment in either patient group. 
Sputum cell counts were not different following placebo 
and BAY 19-8004 treatment in COPD and asthma patients. 
In patients with COPD, small but signiﬁ  cant reductions in 
sputum levels of albumin and eosinophil cationic protein 
were observed. Thus, a 1-week treatment with BAY 19-8004 
did not affect FEV1 or sputum cell numbers in patients with 
COPD or asthma. However, such treatment did reduce levels 
of albumin and eosinophil cationic protein in sputum samples 
obtained from patients with COPD (Grootendorst, Gauw, 
Benschop et al 2003).
Other PDE 4 inhibitors for COPD 
in development
CC3
CC3 is another PDE 4 inhibitor with low afﬁ  nity for the 
HARBS. Its airway-relaxing properties were analyzed using 
rat precision-cut lung slices (PCLS) in which airways were 
contracted by methacholine or in passively sensitized PCLS 
exposed to ovalbumin. The anti-inﬂ  ammatory properties 
were investigated by measuring the release of TNF from 
endotoxin-treated human monocytes. CC3 in combination 
with motapizone, attenuated methacholine-induced 
bronchoconstriction in a concentration-dependent manner. 
CC3 has bronchospasmolytic and anti-inﬂ  ammatory proper-
ties (Martin et al 2002).
AWD 12-281
AWD 12-281 (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-
ﬂ  uorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), is 
a potent (IC50 = 9.7 nM) and selective inhibitor of PDE 4, with 
a low afﬁ  nity for the HARBS (Kuss et al 2003; Gutke et al 
2005). The compound was optimized for topical treatment of 
COPD, asthma, and allergic rhinitis. The compound has a low 
oral bioavailability and a low solubility. It exerts long-lasting 
pharmacological effects after intratracheal administration, 
indicating persistence in lung tissue in various animal models. 
It has high plasma-protein binding and hepatic metabolism 
(primarily glucuronidation); both contribute to low systemic 
exposure after intratracheal dosing. The drug has a large dif-
ference between emetic and anti-inﬂ  ammatory dose levels 
(a factor of more than 100 in ferrets) (Kuss et al 2003).
SCH 351591
SCH 351591 (N-(3,5-dichloro-1-oxido-4-pyridinyl)-
8-methoxy-2-(triﬂ  uoromethyl)-5-quinoline carboxamide) 
has been identiﬁ  ed as a potent (IC50 = 58 nM) and highly 
selective PDE 4 inhibitor with oral bioactivity in several 
animal models of lung inﬂ  ammation and is being investigated 
as a potential therapeutic for COPD and asthma.
Ciclamilast
Ciclamilast is a piclamilast (RP 73-401) analog, though is 
a more potent inhibitor of PDE 4 and airway inﬂ  ammation 
and has a more favorable side-effect proﬁ  le than piclamilast 
(Deng et al 2006). In a murine model, oral administration 
of ciclamilast dose-dependently inhibited changes in lung 
resistance and lung dynamic compliance, up-regulated 
cAMP-PDE activity, and increased PDE 4D, but not PDE 
4B, mRNA expression in lung tissue. Ciclamilast also dose-
dependently reduced mRNA expression of eotaxin, TNF-α 
and IL-4, but increased mRNA expression of IFN-γ in lung 
tissue. There was a correlation between increases in PDE 
4D mRNA expression and airway hyper-responsiveness 
(Deng et al 2006).
Piclamilast
Piclamilast (RP 73-401) reduced antigen challenge induced-
cell recruitment in airways of sensitized mice, and reduced 
gelatinase B (MMP-9) (Belleguic et al 2000). Piclamilast 
also reduced MMP-9 activity and TGF-β1 release during 
acute lung injury in mice, suggesting that PDE 4 inhibitors 
might modulate tissue remodeling in lung injury (Corbel, 
Germain et al 2002). Fibroblasts cultured with PMA or 
TNF-α released increased amounts of pro-MMP-1, whereas 
TGF-β1 had no effect (Martin-Chouly et al 2004). Incuba-
tion with CI-1044 or cilomilast signiﬁ  cantly prevented the 
TNF-α increase in pro-MMP-1. These results suggest that 
PDE 4 inhibitors are effective in inhibiting the pro-MMP-2 
and pro-MMP-1 secretion induced by TNF-α and might International Journal of COPD 2007:2(4) 526
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indicate the potential therapeutic beneﬁ  t of selective PDE 4 
inhibitors in lung diseases associated with abnormal tissue 
remodeling (Martin-Chouly et al 2004).
CGH2466
CGH2466 resulted from a study to identify a theophylline-
like compound with improved effectiveness. CGH2466 
antagonized the adenosine A1, A2b and A3 receptors and 
inhibited the p38 mitogen-activated protein (MAP) kinases 
α and β and PDE 4D. CGH2466 inhibited the production of 
cytokines and oxygen radicals by human peripheral blood leu-
cocytes in vitro. When given orally or locally into the lungs, 
CGH2466 potently inhibited the ovalbumin- or LPS-induced 
airway inﬂ  ammation in mice (Triﬁ  lieff et al 2005).
The in vitro activity of CI-1044 has been compared with 
that of rolipram and cilomilast and to the glucocorticoid 
dexamethasone in reducing LPS-induced TNF-α release 
in whole blood from COPD patients. In whole blood from 
COPD patients, pre-incubation with PDE 4 inhibitors or 
dexamethasone resulted in a dose-dependent inhibition of 
LPS-induced TNF-α release. There was a similar inhibition 
using whole blood from healthy volunteers, however, at 
higher IC50 values. Thus, CI-1044 inhibited in vitro LPS-
induced TNF-α release in whole blood from COPD patients 
(Ouagued et al 2005).
Other treatments for COPD 
in development
Many other treatments for COPD and asthma are in various 
stages of development (Donnelly and Rogers 2003; Buhl 
and Farmer 2004; Buhl and Farmer 2005; Malhotra et al 
2006). They include aids to smoking cessation (Richmond 
and Zwar 2003), antiproteases, including inhibitors of 
neutrophil elastase (Ohbayashi 2002), matrix metalloprote-
ase inhibitors (Owen 2005; Gueders et al 2006), cathepsin 
inhibitors (de Garavilla et al 2005), selectin antagonists 
(Romano 2005), inhibitors of TNF-α (Spond et al 2003), 
adenosine A2a receptor agonists (Bonneau et al 2005), ω-3 
polyunsaturated fatty acids (Matsuyama et al 2005), inhibi-
tors of mucus hypersecretion (Knight 2004; Rogers and 
Barnes 2006), purinoceptor P2Y2 receptor agonists to 
increase mucus clearance (Kellerman 2002), inhibitors of 
p38 mitogen-activated protein (MAP) kinase (Adcock et al 
2006), inhibitors of NF-κB kinase-2 (IKK2) (Caramori et al 
2004), leukotriene (LT) blockers (Riccioni et al 2004), anti-
chemokine therapy (Panina et al 2006; Hardaker et al 2004), 
anti-cytokine therapy (Chung 2006), statins, angiotensin-
converting enzyme inhibitors, and angiotensin receptor 
blockers (Mancini et al 2006), antioxidant therapy (Bowler 
et al 2004; Owen 2005; MacNee 2005b; Rahman and Kilty 
2006; Hanta et al 2006; Sadowska et al 2006; Rahman and 
Adcock 2006), and activators of histone deacetylase (Adcock 
et al 2005; Antoniu 2006; Kirkham and Rahman 2006; Barnes 
2006; Ito et al 2006).
Conclusion
The concept of PDE 4 inhibitors as treatments for COPD, 
asthma, and other inﬂ  ammatory airway conditions has been 
widely discussed in the literature in recent years and may 
soon come to fruition. Taking one step back, PDE inhibitors 
have proven to be successful drugs. Today, the ﬁ  rst-line oral 
pharmacotherapy for most patients with erectile dysfunction 
is a PDE 5 inhibitor: sildenaﬁ  l (Viagra), tadalaﬁ  l (Cialis), 
or vardenaﬁ  l (Levitra) (Briganti et al 2005; Boswell-Smith, 
Spina, et al 2006). Furthermore, ibudilast, a drug that does 
inhibit PDE 4, is marketed in Japan and is used to treat 
asthma.
There is much preclinical data supporting the use of PDE 
4 inhibitors in treating COPD. In vitro, PDE 4 inhibitors relax 
lung smooth muscle and decrease the production of cytokines 
from inﬂ  ammatory cells (Torphy and Undem 1991; Undem 
et al 1994; Dent and Giembycz 1995; Teixeira et al 1997). 
PDE 4 inhibitors also reduce TNF-α release (Proﬁ  ta et al 
2003). Furthermore, some PDE 4 inhibitors inhibit neutro-
phil degranulation (Jones et al 2005). These inhibitors also 
suppress the activity of many pro-inﬂ  ammatory and immune 
cells (Lipworth 2005).
To date, only limited clinical data is available to assess 
PDE 4 inhibitors. Results from large, phase III COPD 
studies of cilomilast have been reported; cilomilast was 
well-tolerated, improved health status, and lung function, and 
reduced the utilization of healthcare resources and incidence 
of COPD exacerbations. However, the results of these phase 
III trials were somewhat unremarkable and disappointing 
(Giembycz 2006).
Questions remain about both the efﬁ  cacy and safety of 
cilomilast, the one PDE 4 inhibitor to have undergone a full 
clinical program to date. Its efﬁ  cacy has been somewhat 
limited and, furthermore, somewhat inconsistent results 
have been reported; indeed, the FDA has yet to approve 
the drug, apparently because of its limited efﬁ  cacy. In two 
of the four pivotal phase III trials, cilomilast did not reach 
statistical signiﬁ  cance over the placebo. In a 6-week phase 
II study in 424 patients with moderate COPD, signiﬁ  cant 
improvements in lung function were seen in patients receiv-
ing cilomilast. Administered at 15 mg bid, it resulted in International Journal of COPD 2007:2(4) 527
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signiﬁ  cant improvements in FEV1 compared with placebo 
(130 mL versus –30 mL at week 6); FVC and peak expira-
tory ﬂ  ow rate also improved. However, no improvement in 
quality of life (SGRQ) was found. The observed difference 
in FEV1 compared with placebo after 12-weeks was 70 mL 
(10 mL versus -60 mL at week 12; statistically insigniﬁ  cant). 
This was compared with 160 mL (130 mL versus –30 mL at 
week 6) in the larger study, despite patients having similar 
levels of baseline function (Compton et al 1991). In a smaller 
(59-patient) phase II study, no signiﬁ  cant change in FEV1 
was found (Gamble et al 2003).
The FDA expressed concern about cilomilast’s toxicity 
and side effects. Vasculitis was seen in rats at doses lower 
than those used in the phase III studies and GI-related side 
effects were seen in patients receiving cilomilast at three 
times the frequency seen in those taking placebo.
It remains unclear whether the effects of cilomilast on 
lung function are the result of bronchodilator activity or of 
an anti-inﬂ  ammatory effect; the relatively slow improvement 
in FEV1 suggests an anti-inﬂ  ammatory action, not bron-
chodilation. The acute bronchodilating effects of a single 
dose of cilomilast have been assessed in COPD patients. 
FEV1 was measured before and at up to 8 h intervals after 
patients received placebo, cilomilast, or cilomilast and 
inhaled salbutamol (400 μg) and/or ipratropium bromide 
(80 μg). A single dose of cilomilast did not cause acute 
bronchodilation in COPD patients who were responsive to 
inhaled bronchodilators (Grootendorst, Gauw, Baan et al 
2003). Anti-inﬂ  ammatory properties of cilomilast have been 
assessed in several studies. In one, patients with COPD 
received cilomilast (15 mg bid) or placebo for 12-weeks. In 
bronchial biopsies, cilomilast treatment was associated with 
reductions in CD8+ and CD68+ cells; this was the ﬁ  rst report 
of a reduction in airway tissue inﬂ  ammatory cells character-
istic of COPD by any agent (Gamble et al 2003).
While the FDA issued an ‘approvable’ letter for cilomilast 
to treat CODP, signiﬁ  cant safety and efﬁ  cacy issues remain. 
In two of four pivotal phase III studies, the drug failed to 
reach statistical signiﬁ  cance in FEV1 change, the co-primary 
endpoint. Indeed, in the two studies that did, this was largely 
the result of decreases in FEV1 in the placebo group, not 
increases in those receiving cilomilast (FEV1 remained close 
to baseline, even after 6-months of treatment, in all four 
studies). The FEV1 changes seen were small and there is a 
question as to whether even statistically signiﬁ  cant results 
would be of much clinical signiﬁ  cance. For comparison, the 
changes were smaller than those reported in a meta-analysis 
of theophylline studies (Ram et al 2002). Three of the four 
phase III studies failed to reach statistical signiﬁ  cance in 
SGRQ, the other primary endpoint. However, cilomilast did 
reduce the incidence of exacerbations.
In rat studies, cilomilast was associated with vasculitis 
and death at doses lower than the human dose, although there 
is some reason to believe that rats may be more sensitive to 
PDE inhibitor toxicity (Bian et al 2004). Vasculitis has been 
seen with other PDE inhibitors (Larson et al 1996; Slim et al 
2003). The FDA was apparently not satisﬁ  ed with the inves-
tigation by GSK of patients with GI-related side effects.
Cilomilast seems unlikely to be a replacement for 
existing COPD therapies (supplemental oxygen, inhaled 
bronchodilators, corticosteroids and antibiotics (Sin et al 
2003)). Cilomilast, however, may be a useful additional 
drug (for example, in combination with corticosteroids), 
especially if it can be shown in longer-term studies that the 
increases in FEV1 are more substantial. Cilomilast has other 
anti-inﬂ  ammatory properties, which may also be of clinical 
signiﬁ  cance (Gamble et al 2003).
The concept of using PDE 4 inhibitors to treat COPD 
may well be sound, but the ﬁ  rst drug in the class may be 
roﬂ  umilast (Antoniu 2006b), not cilomilast. The comple-
tion and publication of its clinical development is awaited 
with interest.
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